From Medscape Special Reports

Special Report: Renal Denervation Derailed?

May 2, 2014


A single-blinded, randomized comparison of catheter-based renal denervation vs sham procedure in patients with resistant hypertension.


Confessions of a SYMPLICITY HTN-3 Trialist
Dr. Seth Bilazarian reflects on the negative results for renal denervation, and the need for alternatives to multiple drugs for severe hypertension.

The SYMPLICITY HTN-3 Co-PI Gives His 2 Cents
Co-PI Dr. George Bakris shares his perspective on what went wrong with the SYMPLICITY HTN-3 trial, and where it leaves renal denervation.

Registry vs RCT Data on Renal Denervation
Dr. Felix Mahfoud comments on the differences between the SYMPLICITY HTN-3 trial and the global registry on renal denervation.

5 Lessons to Be Learned From the Fall of Renal Denervation
Dr John Mandrola evaluates the SYMPLITY-HTN 3 fallout: yet again, physicians were seduced by the seemingly easy solution to a chronic disease better treated with lifestyle modification.

Any Hope for Renal Denervation After SYMPLICITY HTN-3?
Drs. Brady and Gulati discuss whether the operators achieved correct renal denervation in the sham-controlled SYMPLICITY HTN-3 trial.


SYMPLICITY HTN-3: Renal Denervation Fails to Reduce BP in Resistant-Hypertension Patients
The negative study, which included a sham-procedure control arm, highlights the importance of conducting well-designed studies before approving new therapies, say investigators and the editorialists.

SYMPLICITY Registry Data Spur Further Debate on Role of Renal Denervation
Just a day after negative findings of the SYMPLICITY HTN-3 study were presented, registry data show renal denervation did result in significant reductions in systolic BP.

Medscape© WebMD, LLC

Editor’s Note

Has the renal denervation train been derailed after SYMPLICITY HTN-3 showed no difference in blood pressure lowering between it and sham control? Or should we just delay further study until there is a method to verify whether the procedure is done correctly? Experts, including regular columnists and partners (some of whom were involved in the trial), give their points of view.
- Tricia Ward, Editorial Director, | Medscape Cardiology


Hypertensive Heart Disease